Cephalon Reinvention Puts Biologics Front And Center
This article was originally published in Pharmaceutical Approvals Monthly
Through several acquisitions and alliances completed over the last year, Cephalon has patched together a substantial pipeline of biologic drugs, an area of business the specialty pharma is ramping up as it looks to diversify its portfolio beyond wakefulness and pain.
You may also be interested in...
Cephalon hopes BioAssets' sciatic pain proof-of-concept study for etanercept will pave a development path for its anti-TNF.
Look for Cephalon to “roll up” more assets this year while the market is good, CEO Baldino says at J.P. Morgan.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011